Related Experiment Video
Updated: Mar 23, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
TRIM44 as a Multifunctional Regulator in Cancer and Non-Cancer Diseases: From Oncogenic Driver to Immune and Stress
Guive Sharifi1,2, Tohid Emami Meybodi3,4, Fatemeh Jayervand5
1Department of Neurosurgery, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Tripartite motif-containing protein 44 (TRIM44), a unique member of the TRIM family that lacks the canonical RING domain, has recently attracted significant attention for its broad oncogenic potential across diverse malignancies. Accumulating evidence indicates that TRIM44 is markedly overexpressed in cancers, including colorectal, gastric, lung, breast, ovarian, and prostate carcinomas, as well as glioblastoma, multiple myeloma, and hepatocellular carcinoma. Mechanistically, TRIM44 drives tumor progression by modulating critical signaling pathways, including PI3K/AKT/mTOR, NF-κB, Wnt/β-catenin, and epithelial-mesenchymal transition (EMT), primarily through stabilizing regulatory proteins or participating in non-coding RNA- mediated networks. In addition to its role in cancer, TRIM44 has been implicated in cardiovascular dysfunction, ischemia-reperfusion injury, diabetic complications, and neuroinflammation, underscoring its biological versatility. This review provides an overview of current evidence regarding the multifaceted roles of TRIM44 in both oncogenic and non-oncogenic diseases. By integrating insights from oncology, cardiology, neurology, and metabolic research, this review offers a unified perspective on TRIM44 as a pivotal molecular hub and an emerging diagnostic and therapeutic target.
More Related Videos
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...